hVIVO (LON:HVO) Insider Brendan Buckley Sells 2,017,000 Shares

Key Points

• Insider sale: Brendan Buckley sold 2,017,000 shares at an average of GBX 9 on April 24, generating proceeds of £181,530.
• Trading and fundamentals: hVIVO traded at GBX 7.75 on the day with heavy volume (8.28m vs. a 3.71m average), has a market cap of £53.35m, and reported a negative quarterly EPS (GBX -0.87) with negative net margin (‑12.48%) and ROE (‑14.65%).
• Analyst view: The consensus is a "Moderate Buy" with an average price target of GBX 15 (two Buys, one Hold); Shore Capital reiterated Buy while Stifel maintained a Hold with a GBX 10 target.

hVIVO plc (LON:HVO - Get Free Report) insider Brendan Buckley sold 2,017,000 shares of the stock in a transaction that occurred on Friday, April 24th. The shares were sold at an average price of GBX 9, for a total value of £181,530.

hVIVO Stock Performance

Shares of LON HVO traded up GBX 0.15 during trading hours on Friday, reaching GBX 7.75. 8,278,495 shares of the stock were exchanged, compared to its average volume of 3,706,620. The firm has a market capitalization of £53.35 million, a price-to-earnings ratio of 10.06 and a beta of 1.67. The company has a debt-to-equity ratio of 38.75, a quick ratio of 1.16 and a current ratio of 1.63. hVIVO plc has a 52 week low of GBX 4.31 and a 52 week high of GBX 19.50. The stock's fifty day simple moving average is GBX 7.91 and its 200 day simple moving average is GBX 6.88.

hVIVO (LON:HVO - Get Free Report) last released its quarterly earnings data on Wednesday, April 15th. The company reported GBX (0.87) earnings per share for the quarter. hVIVO had a negative net margin of 12.48% and a negative return on equity of 14.65%. The firm had revenue of GBX 4,677 million for the quarter. Sell-side analysts predict that hVIVO plc will post 1.5492958 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on HVO. Shore Capital Group reiterated a "buy" rating on shares of hVIVO in a research report on Wednesday. Stifel Nicolaus reaffirmed a "hold" rating and set a GBX 10 target price on shares of hVIVO in a research note on Wednesday, April 15th. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of GBX 15.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.